206 related articles for article (PubMed ID: 26033453)
1. Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
Stückrath I; Rack B; Janni W; Jäger B; Pantel K; Schwarzenbach H
Oncotarget; 2015 May; 6(15):13387-401. PubMed ID: 26033453
[TBL] [Abstract][Full Text] [Related]
2. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.
Eichelser C; Flesch-Janys D; Chang-Claude J; Pantel K; Schwarzenbach H
Clin Chem; 2013 Oct; 59(10):1489-96. PubMed ID: 23748853
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients.
Kumar S; Keerthana R; Pazhanimuthu A; Perumal P
Indian J Biochem Biophys; 2013 Jun; 50(3):210-4. PubMed ID: 23898484
[TBL] [Abstract][Full Text] [Related]
4. Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients.
Markou A; Zavridou M; Sourvinou I; Yousef G; Kounelis S; Malamos N; Georgoulias V; Lianidou E
Clin Chem; 2016 Jul; 62(7):1002-11. PubMed ID: 27197674
[TBL] [Abstract][Full Text] [Related]
5. Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
Lehmann TP; Korski K; Gryczka R; Ibbs M; Thieleman A; Grodecka-Gazdecka S; Jagodziński PP
Mol Med Rep; 2015 Sep; 12(3):4692-4702. PubMed ID: 26130254
[TBL] [Abstract][Full Text] [Related]
6. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of color Doppler ultrasound combined with plasma miR-21 and miR-27a in the diagnosis of breast cancer.
Li M; Li Q; Yin Q; Wang Y; Shang JM; Wang LH
Clin Transl Oncol; 2021 Apr; 23(4):709-717. PubMed ID: 33206330
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A.
Pan Y; Wang R; Zhang F; Chen Y; Lv Q; Long G; Yang K
Int J Clin Exp Pathol; 2015; 8(1):384-93. PubMed ID: 25755726
[TBL] [Abstract][Full Text] [Related]
9. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
Wang B; Li J; Sun M; Sun L; Zhang X
IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
[TBL] [Abstract][Full Text] [Related]
10. Associations of miR-146a and miR-146b expression and breast cancer in very young women.
Li Y; Xu Y; Yu C; Zuo W
Cancer Biomark; 2015; 15(6):881-7. PubMed ID: 26406414
[TBL] [Abstract][Full Text] [Related]
11. Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
Kim SY; Jeon TY; Choi CI; Kim DH; Kim DH; Kim GH; Ryu DY; Lee BE; Kim HH
J Mol Diagn; 2013 Sep; 15(5):661-9. PubMed ID: 23806809
[TBL] [Abstract][Full Text] [Related]
12. Functional SNP in stem of mir-146a affects Her2 status and breast cancer survival.
Meshkat M; Tanha HM; Naeini MM; Ghaedi K; Sanati MH; Meshkat M; Bagheri F
Cancer Biomark; 2016 Jul; 17(2):213-22. PubMed ID: 27434289
[TBL] [Abstract][Full Text] [Related]
13. MiR-4728-3p could act as a marker of HER2 status.
Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
[TBL] [Abstract][Full Text] [Related]
14. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.
Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F
J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600
[TBL] [Abstract][Full Text] [Related]
16. Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients.
Ota D; Mimori K; Yokobori T; Iwatsuki M; Kataoka A; Masuda N; Ishii H; Ohno S; Mori M
Int J Oncol; 2011 Apr; 38(4):955-62. PubMed ID: 21271219
[TBL] [Abstract][Full Text] [Related]
17. Study on the relationship between miR-520g and the development of breast cancer.
Ren GB; Wang L; Zhang FH; Meng XR; Mao ZP
Eur Rev Med Pharmacol Sci; 2016; 20(4):657-63. PubMed ID: 26957267
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of serum miR-21 in the pathogenesis of familial and triple negative breast cancer.
Yang L; Feng Y; Qi P; Xu S; Zhou Y
J Biol Regul Homeost Agents; 2016; 30(4):1041-1045. PubMed ID: 28078851
[TBL] [Abstract][Full Text] [Related]
19. miR-21: A gene of dual regulation in breast cancer.
Zhang C; Liu K; Li T; Fang J; Ding Y; Sun L; Tu T; Jiang X; Du S; Hu J; Zhu W; Chen H; Sun X
Int J Oncol; 2016 Jan; 48(1):161-72. PubMed ID: 26549725
[TBL] [Abstract][Full Text] [Related]
20. Expression and polymorphism of micro-RNA according to body mass index and breast cancer presentation in Tunisian patients.
Belaiba F; Medimegh I; Ammar M; Jemni F; Mezlini A; Romdhane KB; Cherni L; Benammar Elgaaïed A
J Leukoc Biol; 2019 Feb; 105(2):317-327. PubMed ID: 30303554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
